CSL Ltd shares recover amid growing demand for plasma medicines

CSL Ltd has seen a significant share price recovery, rising 6.9% since the start of 2025. The biotechnology company operates through three primary divisions: CSL Behring, which focuses on blood plasma products; CSL Seqirus, which handles flu-related products and pandemic services; and CSL Vifor, which specializes in iron deficiency and nephrology.

Investors have shown renewed optimism due to the company's leadership in plasma-derived medicines and the growing global demand for these treatments. To improve efficiency and address rising collection costs, CSL has announced an expanded relationship with Haemonetics. This partnership aims to implement new plasma collection technology across CSL’s United States collection centers by the end of 2027.